Open AccessLack of an Effect of a Novel β3-Adrenoceptor Agonist, TAK-677, on Energy Metabolism in Obese Individuals: A Double-Blind, Placebo-Controlled Randomized Study
Author(s) -
Leanne M. Redman,
Lilian de Jonge,
Xiaobing Fang,
Betsy Gamlin,
David P. Recker,
Frank L. Greenway,
Steven R. Smith,
Éric Ravussin
Publication year - 2006
Publication title -
the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2006-1740
Subject(s) - medicine , placebo , endocrinology , body mass index , respiratory quotient , pathology , alternative medicine
Our objective was to test the safety and metabolic effects of a novel beta(3)-adrenoreceptor agonist (TAK-677) in humans.